Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced new real-world preliminary data from the OPTION-VMS Phase IV, longitudinal, observational study, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback